NFL Biosciences S.A. (ALNFL.PA)
NFL Biosciences S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Castelnau-le-Lez, OCC, FR. The stock last traded at $0.86, down 1.94% on the session, giving a market capitalisation of $10.9M. Its beta of 1.15 implies it has historically moved more than the broad market.
Established in 2006 and headquartered in Castelnau-le-Lez, France, NFL Biosciences S.A. is a biotechnology enterprise dedicated to pioneering natural remedies for addiction cessation, particularly for individuals seeking to quit smoking. Their most advanced therapeutic candidate, NFL-101, derived from tobacco, is currently progressing through Phase III clinical trials specifically designed to combat smoking addiction. Additionally, the company's research pipeline features NFL-201, an extract blending cannabis and tobacco, and NFL-301, a botanical formulation rooted in traditional Chinese medicine, both of which are undergoing preclinical assessment.
NFL Biosciences S.A. is most often compared with the following Healthcare names: